Under normal conditions intestinal mucosa presents a baseline "physiological inflammation"
caused by a controlled immune response that eliminates offending dietary and microbial
antigens. This inflammation disappears once the cause is eradicated. In case of inappropriate
immunological response, the inflammation becomes chronic and harmful, resulting in anatomical
and functional abnormalities, namely inflammatory bowel disease (IBD).
Although it is critical for the IBD patients to undergo early diagnosis and management before
the development of severe complications, but as IBD has vague and non-pathognomonic clinical
features, the clinician is usually mislead into late suspicion and detection of IBD.
Diagnosis traditionally depended on a combination of pathologic evaluation together with the
histological, clinical, radiological, endoscopic, surgical, laboratory (serological)
features. Recently, serological markers were identified and became of special interest as
they do not only detect the occurrence of IBD but also the potential of its development and
may be used as prognostic tools. More recently, stool markers were detected and used for
Up to now, the market is still lacking a definitive, simple and non-invasive diagnostic tool.
Saliva can present an alternative form of body fluids that simplify diagnostic procedures.
Our hypothesis is that IBD patients have special salivary biomarkers that may be identified
through salivary analysis, where later on a simple non-invasive test can be applied in the
form of an easy-to-use kit, being available at the clinician's clinic for the establishment
of an immediate and early diagnosis of the destructive inflammatory bowel disease.